breast%20cancer
BREAST CANCER
Breast cancer is the presence of malignant breast nodule, mass or abscess.
Most common symptom of breast cancer is a new lump or mass in the breast. The lump or mass is usually painless, hard & irregular but it can also be tender, soft, rounded or painful.
Other signs & symptoms include breast pain or nipple pain, nipple discharge, nipple retraction and presence of breast skin changes (eg peau d' orange, nipple excoriation, scaling, inflammation, skin tethering, ulceration, abscess).
Drug Information

Indication: Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemother...

Indication: Palliative treatment of hormone-dependent advanced prostate cancer. High-risk localized & locally advanced...

Halaven
eribulin mesylate

Indication: Locally advanced or metastatic breast cancer who have progressed after at least 2 chemotherapeutic regimen for...

Indication: In combination w/ letrozole for the treatment of postmenopausal women w/ estrogen receptor (ER) +ve, human epi...

Indication: Regression in neoplastic conditions eg, acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue & bone ...

Indication: Tab: Multiple myeloma, advanced ovarian adenocarcinoma, breast carcinoma, polycythaemia rubra vera. Inj: Local...

Indication: Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clin...

Indication: Primary treatment of ovarian cancer in combination w/ platinum agent. Metastatic ovarian or breast cancer, aft...

Indication: Adjuvant treatment of post-menopausal women w/ estrogen receptor +ve early breast cancer who have received 2-3...

Indication: In combination w/ fluoropyrimidine-based chemotherapy for metastatic colon or rectum carcinoma. In combination...

1  /  8
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Pearl Toh, 28 Aug 2019
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.
Audrey Abella, 28 Aug 2019
A pooled analysis of six trials failed to show noninferiority of a 3-month regimen to a 6-month regimen of oxaliplatin-based chemotherapy for patients with high-risk, stage II colorectal cancer (CRC).